AlphAIAlphAI — Financial news for AI agents
investing.comOCT 272 min read$ONCY

Oncolytics reports 15-month response duration in anal cancer trial

Oncolytics Biotech (NASDAQ:ONCY) reported updated data from its Phase 1/2 GOBLET study, showing a 15-month median response duration for pelareorep combined with atezolizumab in anal cancer patients, compared to 9.5 months for FDA-approved retifanlimab. The company plans further studies and potential expansion into HPV-associated head and neck cancer.

Original reporting
investing.com
Published Oct 27, 2026, 1:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 1:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$ONCY
Bullish
medium confidence
Mentioned
$ONCY
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ONCYBullishMed
01

Why it matters

The 15‑month median response duration exceeds the 9.5‑month benchmark, potentially enhancing the company's valuation and pipeline perception.

02

Market read

First disclosure of longer response duration could drive short‑term share price appreciation and influence sector sentiment.

03

What to watch

Regulatory timeline and reimbursement landscape could limit upside despite positive data.

Relevance 9/10Novelty 9/10Timing: today

Background

Oncolytics Biotech (NASDAQ:ONCY) released updated Phase 1/2 GOBLET trial results for pelareorep plus atezolizumab in anal cancer.

Company-level read

Ticker impact

$ONCYBullishMedium confidence
Context

Oncolytics Biotech reports a median 15‑month response duration in its anal cancer trial, the first disclosure of these data.

Expected impact

potential upside as market prices in longer response duration

Evidence & confidence

First report of extended response suggests stronger efficacy, likely attracting investor interest.

Market effects

Sector

May boost sentiment for oncolytic virotherapy and biotech firms developing immunotherapies.

Regional

Limited to US biotech sector; European trial sites have minor effect.

Global

Highlights potential for HPV‑associated cancer treatments worldwide.

Counterpoint

What could challenge this read

Data may not translate to commercial success without larger trials; investors should be cautious.

Key entities

  • company
    Oncolytics Biotech Inc.

    Clinical‑stage biotech developing pelareorep.

  • drug
    Atezolizumab

    Checkpoint inhibitor used in combination therapy.

Read at source← All news

StoryOncolytics reports ~15‑month median response duration for pelareorep plus atezolizumab in anal cancer

Also covered by

1 outlet

Related articles

NOV 4
$ONCYHighAI 9/10

Oncolytics Biotech Reports Pelareorep-Driven HPV Immune Responses in Anal Cancer Study

Oncolytics Biotech reported that pelareorep increased HPV-specific immune responses in anal cancer patients. Seven of eight patients showed significant biomarker increases after one cycle, and all four evaluable patients had tumor shrinkage after three cycles. The study showed improved response rates and duration compared to current therapies. The Phase 1/2 study combines pelareorep with a checkpoint inhibitor.

tradingview.com1 min
NOV 4
$ONCYMedAI 8/10

ONCOLYTICS BIOTECH INC (ONCY): Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers Pelareorep-driven changes in the tumor microenvironment are associated with tumor responses and shrinkage Immune activation levels

SEC EDGAR 8-K2 min
NOV 4
$ONCYMedAI 8/10

Immune-cell expansion accompanied tumor shrinkage in four anal cancer patients

Oncolytics Biotech (ONCY) reported data from a study showing pelareorep, its investigational immunotherapy, increased HPV-16-specific T cells and tumor-infiltrating lymphocytes in anal cancer patients. The treatment, combined with a checkpoint inhibitor, led to tumor shrinkage in four patients, including two complete responses. The Phase 1/2 study is evaluating the safety and efficacy of the combination therapy in unresectable anal cancer patients.

stocktitan.net2 min
OCT 28
$ONCYMedAI 8/10

Pelareorep Plus Atezolizumab Generates Durable Responses in Previously Treated SCAC

Oncolytics Biotech reported updated data from the GOBLET trial showing durable responses and extended survival in patients with squamous cell anal cancer (SCAC) treated with pelareorep and atezolizumab. The median duration of response was approximately 15 months, and all responding patients survived beyond 12 months. The company plans to pursue registration in SCAC and explore additional studies in other HPV-associated cancers.

onclive.com2 min
OCT 27
$ONCYMedAI 8/10

Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven…

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Oncolytics Biotech ® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers GOBLET Cohort 4 demonstrates approximately 15-month median duration of response that exceeds historical results fo

SEC EDGAR 8-K2 min